TLDR:
- VC investments in the medtech sector totaled $3.3 billion in Q2 of 2024.
- $539.4 million was invested in cardiovascular technologies.
Full Article:
Venture capital (VC) investments in the healthcare technology sector remained strong in the second quarter of 2024, reaching a total of $3.3 billion in deal value. Although this was slightly lower than the first quarter of the year, it still showed an increase from the previous year. This positive trend was highlighted in a Pitchbook report focused on VC and private equity (PE) investments in medtech.
The quarter was led by a significant investment of $539.4 million in cardiovascular technologies. Other high-ranking subsegments included diagnostics ($403.2 million) and surgical implants ($287.1 million). HeartFlow emerged as a key player in the industry, having raised $828.6 million in venture capital investments, positioning it as the third-highest funded company evaluated in the report.
The report also mentioned Johnson & Johnson’s acquisition of Shockwave Medical for $13.1 billion as a notable deal, indicating that strategic investments could pay off for the right opportunities. While medtech PE activity was slightly down, 2023 was a strong year in terms of PE investments.
Overall, the report concluded that the VC exit levels in the medtech sector for 2024 were positive, signaling a solid win for the industry and indicating potential for increased deal value and exit momentum in the future.
